Table 3.
Univariable and multivariable analyses of the associations with allograft failure in transplant patients with kidney failure secondary to IgAN
| Variable | Univariable (n = 282) |
Multivariable (n = 282), N events = 60 |
|||
|---|---|---|---|---|---|
| N events | HR (95% CI) | p value | HR (95% CI) | p value | |
| Recipient age at transplant (per each year) | 60 | 0.98 (0.96–1.00) | 0.09 | 0.97 (0.94–0.99) | 0.02 |
| Recipient, female gender | 60 | 0.88 (0.50–1.54) | 0.66 | ||
| Recipient, European ancestry | 60 | 0.91 (0.54–1.56) | 0.74 | ||
| Donor recipient, European ancestry | 41 | 2.07 (0.87–4.94) | 0.1 | ||
| Allograft from living donor | 60 | 0.56 (0.34–0.95) | 0.03 | 0.36 (0.19–0.67) | 0.001 |
| Medical sites | 60 | ||||
| CUIMC | Ref | − | Ref | − | |
| OHSU | 1.70 (0.96–3.01) | 0.07 | 0.89 (0.41–1.92) | 0.77 | |
| HUC | 0.95 (0.39–2.29) | 0.9 | 0.39 (0.14–1.11) | 0.08 | |
| Year of transplantation | 60 | 1.07 (1.01–1.15) | 0.03 | 1.16 (1.08–1.25) | <0.001 |
| Recurrence of IgAN | 60 | 1.89 (1.12–3.19) | 0.02 | 2.45 (1.38–4.36) | 0.002 |
| # HLA matches (per antigen: 0–6) | 60 | 0.86 (0.74–0.99) | 0.04 | 0.87 (0.73–1.04) | 0.13 |
| Induction with thymoglobulin | 56 | 0.91 (0.52–1.59) | 0.73 | ||
| Steroid-free regimens | 60 | 0.54 (0.29–0.98) | 0.04 | 0.59 (0.26–1.30) | 0.19 |
| Acute rejection | 60 | 2.46 (1.46–4.16) | 0.001 | 2.68 (1.51–4.76) | 0.001 |
| Recipient HLA-B35 | 60 | 1.29 (0.74–2.24) | 0.37 | ||
| Recipient HLA-DQ5 | 57 | 1.07 (0.62–1.84) | 0.82 | ||
| Recipient HLA-DR3 (DR17 or 18) | 60 | 1.05 (0.49–2.22) | 0.91 | ||
| Recipient HLA-DR15 | 60 | 1.90 (1.08–3.35) | 0.02 | 1.90 (1.04–3.47) | 0.04 |
| Recipient HLA-DQ6 | 57 | 1.44 (0.83–2.51) | 0.2 | ||
| Recipient HLA-DQ2 | 57 | 0.63 (0.33–1.20) | 0.16 | ||
| Donor HLA-B35 | 60 | 0.97 (0.51–1.83) | 0.92 | ||
| DonorHLA-DQ5 | 57 | 1.07 (0.59–1.91) | 0.83 | ||
| Donor HLA-DR3 (DR17 or 18) | 60 | 1.06 (0.53–2.10) | 0.88 | ||
| Donor HLA-DR15 | 60 | 1.23 (0.71–2.30) | 0.42 | ||
| Donor HLA-DQ6 | 57 | 1.47 (0.84–2.56) | 0.18 | ||
| DonorHLA-DQ2 | 57 | 1.01 (0.55–1.86) | 0.97 | ||
| Pretransplant DSA | 55 | 1.02 (0.25–4.22) | 0.8 | ||
Rejection is defined as any episode of acute rejection encountered during the follow-up period.
CUIMC, Columbia University Irving Medical center; DSA, donor-specific antibodies; OHSU, Oregon Health & Science University; HUC, Hospitais da Universidade de Coimbra; DSA, donor-specific autoantibodies; IgAN, IgA nephropathy; HLA, human leukocyte antigen.